Troglitazone

Caroline Day*, Clifford J. Bailey

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

Troglitazone was the first thiazolidinedione antihyperglycemic agent to be introduced for the treatment of type 2 diabetes mellitus. It was introduced in 1997, but withdrawn almost immediately (UK) or by 2000 (USA) as evidence emerged of fatal idiosyncratic hepatotoxicity... © 2007

Original languageEnglish
Title of host publicationxPharm
Subtitle of host publicationthe comprehensive pharmacology reference
PublisherElsevier
Number of pages3
ISBN (Print)978-0-08-055232-3
DOIs
Publication statusPublished - Feb 2011

Fingerprint Dive into the research topics of 'Troglitazone'. Together they form a unique fingerprint.

  • Research Output

    • 6 Chapter (peer-reviewed)

    Biguanides

    Day, C. & Bailey, C. J., Feb 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 3 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

  • Ciglitazone

    Day, C. & Bailey, C. J., Feb 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 2 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

  • Metformin

    Day, C. & Bailey, C. J., 1 Dec 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 4 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

  • Cite this

    Day, C., & Bailey, C. J. (2011). Troglitazone. In xPharm: the comprehensive pharmacology reference Elsevier. https://doi.org/10.1016/B978-008055232-3.62812-0